Literature DB >> 18781585

Skin toxicity caused by EGFR antagonists-an autoinflammatory condition triggered by deregulated IL-1 signaling?

Ulrich Rodeck1.   

Abstract

Acneiform skin eruptions associated with sterile inflammation frequently accompany pharmacological inhibition of signaling through the epidermal growth factor receptor (EGFR) in cancer patients. Here we discuss possible pathogenic mechanisms for this phenomenon linked to control of inflammatory mediators by EGFR blockade in keratinocytes of the outer root sheath of the hair follicle. This discussion is focused on the putative role of EGFR activation in restraining interleukin (IL)-1-dependent inflammatory networks at the hair follicle. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18781585     DOI: 10.1002/jcp.21585

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  5 in total

Review 1.  Recent advances on the roles of epidermal growth factor receptor in psoriasis.

Authors:  Sijia Wang; Zhuoli Zhang; Han Peng; Kang Zeng
Journal:  Am J Transl Res       Date:  2019-02-15       Impact factor: 4.060

2.  Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.

Authors:  Joshua M Donaldson; Csaba Kari; Ruben C Fragoso; Ulrich Rodeck; John C Williams
Journal:  Cancer Biol Ther       Date:  2009-11-07       Impact factor: 4.742

Review 3.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors:  Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal:  Oncol Rep       Date:  2020-12-24       Impact factor: 3.906

Review 4.  Mechanisms underlying skin disorders induced by EGFR inhibitors.

Authors:  Martin Holcmann; Maria Sibilia
Journal:  Mol Cell Oncol       Date:  2015-06-01

5.  Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.

Authors:  Aditya Stanam; Katherine N Gibson-Corley; Laurie Love-Homan; Nnamdi Ihejirika; Andrean L Simons
Journal:  Oncotarget       Date:  2016-11-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.